Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Summary: Myeloid neoplasms derive from the pathological clonal expansion of an abnormal stem cell and span a diverse spectrum of phenotypes including acute myeloid leukaemia (AML), myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS). Expansion of myeloid blasts with suppression of normal haematopoiesis is the hallmark of AML, whereas MPN is associated with over‐proliferation of one or more lineages that retain the capacity to differentiate, and MDS is characterized by cytopenias and aberrant differentiation. MPD and MDS can progress to AML, which is likely due to the acquisition of cooperative mutations. Juvenile myelomonocytic leukaemia (JMML) is an aggressive myeloid neoplasm of childhood that is clinically characterized by overproduction of monocytic cells that can infiltrate organs, including the spleen, liver, gastrointestinal tract, and lung. JMML is categorized as an overlap MPN/MDS by the World Health Organization and also shares some clinical and molecular features with chronic myelomonocytic leukaemia, a similar disease in adults. While the current standard of care for patients with JMML relies on allogeneic haematopoietic stem cell transplant (HSCT), relapse is the most frequent cause of treatment failure. This review outlines our understanding of the genetic underpinnings of JMML with a recent update on the discovery of novel CBL mutations, as well as a brief review on current therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
Neel, B. G., Gu, H., & Pao, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00091-4 · Cited by 1,249 · cited 1×
“The protein tyrosine phosphatase, non-receptor type 11 (PTPN11; SHP2) encoded by PTPN11 includes two Src homology 2 (SH2) domains (termed N-SH2 and C-SH2) and a catalytic protein tyrosine phosphatase (PTP) domain [reviewed in (Neel et al, 2003)].”
BackgroundQuintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843
The Cbl interactome and its functions
Schmidt, M. H. H., & Dikic, I. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1762 · Cited by 395
Braun, B. S., Tuveson, D. A., Kong, N., Le, D. T., Kogan, S. C., Rozmus, J., Le Beau, M. M., Jacks, T. E., & Shannon, K. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307203101 · Cited by 299
Largaespada, D. A., Brannan, C. I., Jenkins, N. A., & Copeland, N. G. (1996) · Nature Genetics · doi:10.1038/ng0296-137 · Cited by 284 · cited 2×
“…to conditionally delete the Nf1 allele, elevated levels of Ras-GTP occur, and myeloproliferative neoplasm (MPN) develops, thus further validating the hypothesis that the absence of normal neurofibromin results in a relative increase in Ras-GTP (Bollag et al, 1996; Largaespada et al, 1996).”
BackgroundChan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Kelly, L., Shigematsu, H., Johnson, L., Akashi, K., Tuveson, D. A., Jacks, T., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20476 · Cited by 270 · cited 1×
“Animal models have subsequently revealed that Kras mutant mice also develop fatal myeloid disorders that resemble JMML in vivo and in vitro (Braun et al, 2004; Chan et al, 2004).”
BackgroundChan, R. J., Leedy, M. B., Munugalavadla, V., Voorhorst, C. S., Li, Y., Yu, M., & Kapur, R. (2005) · Blood · doi:10.1182/blood-2004-10-4002 · Cited by 156 · cited 1×
“Studies of the E76K protein reveal that it displays the highest phosphatase activity, induces profound hypersensitivity to GM-CSF in fetal liver cells, and transforms transduced BaF3 cell lines to cytokine independence (Tartaglia et al, 2003; Chan et al, 2005; Schubbert et al, 2005).”
Background
Cited by
Clonal architecture of chronic myelomonocytic leukemias
Itzykson, R., Kosmider, O., Renneville, A., Morabito, M., Preudhomme, C., Berthon, C., Adès, L., Fenaux, P., Platzbecker, U., Gagey, O., et al. (2013) · Blood · doi:10.1182/blood-2012-06-440347 · Cited by 276
Janus kinase deregulation in leukemia and lymphoma
Chen, E., Staudt, L. M., & Green, A. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.017 · Cited by 123
“RAS or PTPN11 mutations account for 60% of JMMLs and 35% of CMMLs (Loh, 2011).”
Metadata
- Authors
- Loh, M. L.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2011-02-25
- Volume
- 152
- Issue
- 6
- Pages
- 677-687
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2131444433
- Cited by
- 160
- References
- 8
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. https://app.cochat.ai/papers/10.1111/j.1365-2141.2010.08525.x
- The paper
- Loh, M. L. (2011). Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2010.08525.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.